证券代码：688626 证券简称：翔宇医疗 公告编号：2025-042 河南翔宇医疗设备股份有限公司 第三届董事会第六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 河南翔宇医疗设备股份有限公司（以下简称"公司"）第三届董事会第六次 会议于 2025 年 8 月 27 日在公司会议室以现场结合通讯的方式召开。会议通知已 于 2025 年 8 月 17 日送达各位董事。本次会议应出席董事 5 人，实际出席董事 5 人。会议由董事长何永正先生召集并主持，公司监事及高级管理人员列席会议。 会议的召开及表决程序符合有关法律、行政法规、部门规章和《公司章程》的规 定。 二、董事会会议审议情况 经与会董事投票表决，本次会议审议并通过了以下议案： （一）审议通过《关于公司 2025 年半年度报告及其摘要的议案》 公司 2025 年半年度报告的编制和审议程序符合相关法律法规和《公司章程》 等内部规章制度的规定。公司 2025 年半年度报告的内容与格式符合相关规定， 报告内容真实、准确、完整地反映了公 ...

本次会议通过了以下议案: 河南翔宇医疗设备股份有限公司 第三届董事会独立董事专门会议 2025 年第二次会议决议 河南翔宇医疗设备股份有限公司(以下简称"公司")第三届董事会独立董事 专门会议 2025 年第二次会议于 2025 年 8 月 27 日在公司会议室以现场结合通讯 方式召开，会议通知已于 2025 年 8 月 17 日送达各位独立董事。本次会议应出席 独立董事 2 人, 实际出席 2 人，会议由独立董事刘振先生召集并主持。会议的召 集和召开程序符合《上市公司独立董事管理办法》、《公司章程》等有关规定， 会议决议合法、有效。 表决结果：2 票同意，0 票反对，0 票弃权。 河南翔宇医疗设备股份有限公司董事会 独立董事专门会议 2025 年 8 月 27 日 一、审议通过《关于增加 2025 年度日常关联交易预计的议案》 独立董事认为：公司增加 2025 年度日常关联交易预计为公司开展正常生产 经营所需，公司自身业务与关联方的业务存在一定的关联性，存在交易的必要性， 关联交易事项符合公司发展需要。关联交易遵循了公平、公正、合理的原则，关 联交易作价公允，不损害公司及股东特别是中小股东的利益，不会影响公 ...

河南翔宇医疗设备股份有限公司2025 年半年度报告 公司代码：688626 公司简称：翔宇医疗 河南翔宇医疗设备股份有限公司 2025 年半年度报告 1 / 209 河南翔宇医疗设备股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的真实性、准确 性、完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 公司已在本报告中详细阐述了公司在生产经营过程中可能面临的风险，敬请查阅"第三节 管 理层讨论与分析"之"风险因素"，请投资者注意投资风险。 三、 公司全体董事出席董事会会议。 四、 本半年度报告未经审计。 五、 公司负责人何永正、主管会计工作负责人金宏峰及会计机构负责人（会计主管人员）韩俊 声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 无 七、 是否存在公司治理特殊安排等重要事项 九、 是否存在被控股股东及其他关联方非经营性占用资金情况 否 十、 是否存在违反规定决策程序对外提供担保的情况 否 十一、 是否存在半数以上董事无法保证公司 ...

Summary of Key Points Core Viewpoint - The performance of Xiangyu Medical has shown fluctuations in stock price and trading volume, with significant changes in financing activities and revenue generation [1][2]. Group 1: Stock Performance and Financing - On August 26, Xiangyu Medical's stock price dropped by 3.53%, with a trading volume of 183 million yuan [1]. - The financing buy-in amount for Xiangyu Medical on the same day was 27.81 million yuan, while the financing repayment was 36.13 million yuan, resulting in a net financing outflow of 8.32 million yuan [1]. - As of August 26, the total financing and securities lending balance for Xiangyu Medical was 166 million yuan, which accounts for 1.74% of its market capitalization [1]. Group 2: Business Performance - For the period from January to March 2025, Xiangyu Medical reported a revenue of 186 million yuan, reflecting a year-on-year growth of 10.02% [2]. - The net profit attributable to the parent company for the same period was 22.95 million yuan, showing a significant year-on-year decrease of 41.26% [2]. Group 3: Shareholder Information and Dividends - As of March 31, the number of shareholders for Xiangyu Medical was 5,895, which is an increase of 10.48% compared to the previous period [2]. - The company has distributed a total of 277 million yuan in dividends since its A-share listing, with 157 million yuan distributed over the past three years [3]. Group 4: Company Overview - Xiangyu Medical, established on March 20, 2002, is located in Anyang, Henan Province, and specializes in the research, production, and sales of rehabilitation medical devices [1]. - The company's main revenue sources include rehabilitation therapy equipment (67.79%), rehabilitation training equipment (22.13%), and other related products [1].

Group 1 - The core business of the company is the research, production, and sales of rehabilitation medical devices, with a wide range of products including rehabilitation therapy, training, care, assistive devices, assessment, traditional Chinese medicine treatment, health maintenance, medical beauty, and home rehabilitation [2] - As of March 31, 2025, the company had 5,895 shareholders, an increase of 559 from the previous period, with an average holding value of 352,800 yuan and an average holding quantity of 27,600 shares [1] - The company's stock closed at 61.8 yuan on August 25, with a rolling price-to-earnings (PE) ratio of 113.89, significantly higher than the industry average PE of 56.14 [1][3] Group 2 - In the latest quarterly report for Q1 2025, the company achieved a revenue of 186 million yuan, a year-on-year increase of 10.02%, while net profit was 22.95 million yuan, reflecting a year-on-year decrease of 41.26% [3] - The company has received multiple awards for its projects, including first prizes for various rehabilitation technology projects from the Chinese Rehabilitation Medicine Association and other organizations, highlighting its innovation and contribution to the field [2]

Group 1 - The 2025 Henan Brain-Computer Interface Technology Innovation Development Forum was held in Anyang, focusing on the integration of brain-computer interface technology and rehabilitation medicine, attracting experts from various fields [1] - The forum was co-hosted by Henan Provincial People's Hospital and Xi'an Jiaotong University, featuring one main forum and five thematic sub-forums under the theme "Inheriting the Spirit of the Red Flag Canal, Intelligent Rehabilitation for a New Future" [1] - A joint innovation consortium for brain-computer interface rehabilitation technology was established, led by Xiangyu Medical, involving 12 universities and research institutions, aiming to bridge the gap between research, clinical practice, and industry [1] Group 2 - Xiangyu Medical's brain-computer interface laboratory has built an ecosystem covering "collection - algorithm - control - scenario," with its non-invasive EEG collection device receiving national medical device certification [2] - The company plans to complete the development of over 20 related devices this year, leveraging clinical experience from the Provincial People's Hospital and its own R&D capabilities to address issues like signal recognition accuracy [2] - A strategic cooperation agreement was signed between Xiangyu Medical and the Provincial People's Hospital, alongside the global launch of 13 new products in various fields, including lower limb rehabilitation training and cognitive impairment assessment [1][2]

Core Viewpoint - The brain-computer interface (BCI) industry is entering a period of accelerated development, with significant advancements in technology and increasing market opportunities driven by aging populations and supportive policies [1][6]. Product Development Acceleration - BCI technology facilitates information exchange between the brain and external devices, with applications in healthcare, rehabilitation, education, and entertainment [1]. - The medical sector is the most advanced in terms of commercialization, with a projected market size of approximately 71.46 billion yuan for rehabilitation medical devices in 2024 [2]. - Xiangyu Medical has launched five series of BCI products, including solutions for physical therapy, occupational therapy, swallowing and cognition, neuro-rehabilitation, and intelligent rehabilitation care [1][2]. Collaborative Development - Significant progress in underlying technologies such as microelectronics, materials science, and neuroscience has laid the foundation for breakthroughs in BCI [3]. - Xiangyu Medical aims to integrate BCI technology into various rehabilitation equipment, enhancing the application scenarios of their technology [3][4]. Continuous Innovation in Technology - The "Beinao No. 1" intelligent BCI system, developed in collaboration with the Beijing Brain Science and Brain-like Research Institute, is currently in clinical validation, helping patients with movement and speech disabilities [4]. - The integration of industry, academia, and research is accelerating the transformation of technological achievements into clinical rehabilitation products [4][5]. Favorable Policy Environment - Recent government policies, including the establishment of independent billing items for BCI, are providing institutional support for clinical applications [6]. - The BCI investment landscape is active, with over 800 million yuan expected in financing for the first half of 2025 across various subfields [6]. Market Growth Potential - The BCI market in China is projected to reach approximately 2.3 billion yuan in 2024, with expectations to exceed 10 billion yuan by 2029, reflecting a compound annual growth rate of over 35% [6][7]. - The industry is characterized by a high concentration of research and development in non-invasive BCI, which constitutes 86% of the market [6]. Future Trends - The BCI industry is expected to see increased collaboration across sectors, with companies evolving into open ecosystem platforms and more mergers and acquisitions occurring [7]. - Investment in the healthcare sector is anticipated to grow, supported by government funds and private capital, providing ample financial resources for industry development [7].

Core Insights - Brain-computer interface (BCI) technology is entering a period of accelerated development, with companies like Xiangyu Medical launching multiple BCI devices and forming strategic partnerships to enhance clinical applications and technology transfer [1][4] - The market for rehabilitation medical devices in China is projected to reach approximately 71.46 billion yuan in 2024, driven by innovations in BCI products [2] - The BCI industry is experiencing significant technological advancements, with a focus on integrating various fields such as microelectronics, materials science, and neuroscience [3][6] Product Development Acceleration - Xiangyu Medical has introduced five series of BCI products aimed at rehabilitation, including solutions for physical therapy, occupational therapy, and cognitive rehabilitation [1][2] - The BCI PT solution enables precise movement control for patients recovering from strokes and injuries, showcasing the potential for market disruption in rehabilitation technology [2] Industry Collaboration - The collaboration between Xiangyu Medical and Henan Provincial People's Hospital aims to leverage clinical expertise and R&D capabilities to explore innovative applications of BCI technology in rehabilitation [4] - The establishment of joint laboratories and partnerships between companies and research institutions is fostering the integration of research and clinical applications, accelerating the commercialization of BCI technologies [4][5] Policy and Investment Landscape - Recent government policies, including the establishment of independent billing codes for BCI services, are providing a regulatory framework to support the industry's growth [5] - The investment landscape for BCI technology is robust, with significant funding activities projected to exceed 800 million yuan in the first half of 2025, indicating strong investor interest in the sector [5][6] Market Outlook - The BCI market in China is expected to grow from approximately 2.3 billion yuan in 2024 to over 10 billion yuan by 2029, with a compound annual growth rate exceeding 35% [5] - The industry is anticipated to evolve into a trillion-yuan market by 2040, driven by increasing demand and technological advancements [5]

Group 1 - The 2025 Henan Brain-Computer Interface Technology Innovation Development Forum and related events were held in Anyang, focusing on the latest research and breakthroughs in brain-computer interface technology [1][2] - The theme of the conference was "Inheriting the Spirit of the Hongqi Canal, Intelligent Rehabilitation for a New Future," emphasizing the integration of brain-computer interface technology in rehabilitation medicine [1] - Keynote speakers included experts from various universities and research institutions, discussing the rapid development of brain-computer interface technology in China and its potential in enhancing rehabilitation medical services [1][2] Group 2 - The Henan Provincial Department of Industry and Information Technology highlighted brain-computer interfaces as a core area in the future health industry, promoting the integration of AI and robotics [2] - A strategic cooperation agreement was signed between Xiangyu Medical and Henan Provincial People's Hospital to explore innovative applications of brain-computer interface technology in rehabilitation [2] - A new collaborative innovation consortium for brain-computer interface rehabilitation technology was established, aiming to break down barriers between research, clinical practice, and industry [2] Group 3 - Xiangyu Medical launched a global product release for a series of brain-computer interface products, including 13 new items such as lower limb feedback rehabilitation training systems and intelligent care systems [3]

Group 1 - The core business of the company is the research, production, and sales of rehabilitation medical devices, with a wide range of products across 10 categories and over 1,000 products [2] - The company has received multiple awards for its projects, including first prizes for various rehabilitation technology initiatives from different medical and scientific associations [2] - As of the first quarter of 2025, the company reported a revenue of 186 million yuan, a year-on-year increase of 10.02%, while net profit decreased by 41.26% to 22.95 million yuan [3] Group 2 - The company's current rolling price-to-earnings (PE) ratio is 109.54, significantly higher than the industry average of 59.32 and the median of 39.97 [3] - The total market capitalization of the company is 9.51 billion yuan [3] - As of the first quarter of 2025, six institutions hold shares in the company, with a total of 634,800 shares valued at 2.8 million yuan [1]